Given the apparently fixed stoichiometry of the system, and the seemingly absolute requirement for combining GABA B1 and GABA B2 subunits, production of these proteins should be modified as the need for receptors ebbs and flows and should track with changes in receptor function that occur due to long-term perturbations of the system. In particular, such a finding would be expected if GABA B1 and GABA B2 function only as components of GABA B receptors.
One way to test this is to modify receptor function while monitoring the production of the subunits. Previous work established that GABA B receptor subunit expression in the rat spinal cord changes during subchronic formalin-induced inflammatory pain (McCarson and Enna, 1999) , whereas chronic administration of a GABA B receptor agonist, such as baclofen, results in tolerance to the sedative and antinociceptive effects of this agent (Enna et al., 1998) . Using these physiological and pharmacological approaches, the present study was undertaken to characterize the relationship between the expression of GABA B receptor subunits and GABA B receptor activity. The results reveal no correlation between subunit expression and receptor function, suggesting that not all GABA B receptor subunits are incorporated into functional GABA B receptors and that nongenomic mechanisms play a role in regulating receptor availability and function, even following prolonged agonist stimulation.
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Materials and Methods
Animals. Pathogen free male Sprague-Dawley rats (250-300 g; Harlan Farms) were used for all experiments. The animals were maintained on a 12 hour light/dark cycle in the Kansas University Medical Center animal care facility with free access to standard rat chow and water.
The experiments were approved by the Kansas University Medical Center Animal Care and Use
Committee and were performed in accord with institutional guidelines regarding the ethical treatment of animals and the use and disposal of hazardous waste.
Drug Administration and Tissue Preparation.
For some experiments, 5 mg/kg baclofen (β-chlorophenyl GABA), a selective GABA B receptor agonist, was administered (i.p.) twice daily for seven consecutive days. Previous work demonstrated this treatment regimen results in tolerance to the antinociceptive and sedative effects of baclofen (Enna et al., 1998) .
Twenty-four hr following the last dose of baclofen, and immediately following any behavioral tests, the rats were decapitated and spinal cord tissues rapidly removed by a forceful injection of ice cold isotonic saline into the caudal end of the vertebral canal using a 60 ml syringe attached to a 16 gauge needle. For measurement of mRNA, the lumbar portion of the vertebral column was rapidly dissected and frozen at -70Û8ÃvyÃhhrqÃÃAÃvuvpurvÃqvrÃurÃ lumbar region was immediately immersed in 4% paraformaldehyde and refrigerated at 4Û8ÃvyÃ Nociceptive Tests. Nociception was assessed by measuring the time to withdrawal of the paw following a mechanical pinch to the dorsal surface of the hind paw of unrestrained rats using a small vascular clamp calibrated to 250 g/mm 2 (McCarson and Goldstein, 1991) .
For some experiments late-phase nociceptive behaviors were monitored for 10 min beginning 30 to 40 min after injection of formalin. The rats were monitored in a 256 in 2 observation chamber and hind paw flinches counted for one minute periods by an observer blind to treatments (Wheeler-Aceto et al., 1990) .
Analysis of GABA B Receptor mRNAs. Total RNAs were obtained from rat lumbar spinal cord tissue using a rapid guanidinium isothiocyanate-phenol/chloroform extraction and subsequent precipitation with sodium acetate and ethanol (Chomczynski & Sacchi, 1987) . One dorsal quarter of the spinal cord lumbar enlargement routinely provided approximately 50-100 tÃhyÃSI6ÃÃUurÃyrryÃsÃrpvsvpÃSI6ÃsÃrhph GABA B receptor subunit was quantified using solution hybridization-nuclease protection assays.
The GABA B receptor subunit-encoding mRNAs were provided by Dr. Klemens Kaupmann (Novartis, Basel, Switzerland) . Analysis of GABA B1a+b -encoding mRNAs utilized a coding region plasmid pBS GABA B R1pan [+2462 "!"#dÃurrhÃurÃB676 B2 -encoding mRNAs were analyzed using the coding region plasmid pBS GABA B R2[+525 !#%dÃÃ 6hyvÃsÃ -actin mRNA was performed using a coding region plasmid [pBS-6 210 ]. All constructs were used to transcribe antisense probes as well as message-sense cRNAs. Samples of total RNA were assayed for GABA B receptor subunitÃhqÃ -actin mRNAs using a solution hybridization-nuclease protection assay, as described previously Krause, 1994, 1995 labeled antisense cRNA probe and digestion with nucleases A and T 1 . In all cases, the digestion reaction products were precipitated with an equal volume of 2-propanol prior to resuspension and electrophoresis at 25 V/cm on 6% acrylamide gels containing 7 M urea. The gels were fixed, dried, and exposed to phosphor plates (Molecular Dynamics, Sunnyvale, CA) for 16-48 hr.
Densitometric images were generated and analyzed using a Molecular Dynamics Western Blot Analysis. Dorsal lumbar spinal cords were minced using a sterile blade and placed in 4 ml of protein extraction Buffer I (20 mM Hepes, 6 mM MgCl 2 , 1 mM EDTA, 250 mM sucrose, pH 7.4). Tissues were homogenized with a Polytron at maximum speed for 30 sec, followed by centrifugation at 1700 x g for 10 min. The resultant supernatant was centrifuged at 100,000 x g for 60 min, and the pellet resuspended in 50-100 µl of protein extraction Buffer II (20 mM Hepes, 6 mM MgCl 2 , 1 mM EDTA, 1 mM EGTA, pH 7.4).
Portions of this suspension were taken for protein quantification using a bicinchoninic acid assay kit (Sigma Chemical Co., St. Louis, MO). Protein extracts were stored at -20° C until analysis.
For assay, portions of the protein extracts (50-100 µg) were subjected to electrophoreses in a 7.5% polyacrylamide gel and transferred to nitrocellulose membranes using an electrophoretic gel-transfer apparatus (Bio-Rad Laboratories, Hercules, CA). The blots were incubated for 1 hr at room temperature in blocking buffer (5% dry milk-TBS-0.1% Tween 20), followed by a 2 hr incubation in the guinea pig anti-GABA B2 diluted 1:10,000. Following a 1 hr exposure to the goat anti-guinea pig secondary antibody conjugated to horseradish peroxidase, blots were developed using chemiluminescence markers following the manufacturer's protocol (New England Nuclear, Boston, MA). The blots were apposed to x-ray film and densitometric images generated and analyzed using a Molecular Dynamics scanning densitometer. Densitometric signals for the protein samples were quantified using IP LabGen (National Institutes of Health).
This article has not been copyedited and formatted. The final version may differ from this version. until use. For assay, the slides were brought to room temperature and then placed into assay buffer (4 mM MgCl 2 , 160 mM NaCl, 0.267 mM EGTA, 67 mM Tris, pH 7.4) for 10 min, after which they were exposed for 15 min to 2 mM GDP. Incubation buffers (1.25 ml assay buffer, 1.25 ml 8 mM GDP, 1.25 ml [ To assess the effect of persistent nociceptive activation of the GABAergic system on GABA B ÃrprÃivÃrvÃ$ÈÃshyvÃ Ã yÃhÃvwrprqÃiphryÃvÃurÃhÃ hind paw, with lumbar spinal cord GABA B1 and GABA B2 proteins examined histochemically 24
hr later (Fig. 1) . The results revealed a significant increase in both GABA B1 and GABA B2 protein in this region of the spinal cord (Fig. 1, panels B&D) as compared to untreated control animals ( Fig. 1 , panels A&C). While formalin treatment increased GABA B1 and GABA B2 protein levels, there was no significant difference in the regional distribution of these proteins between the two groups, with the highest density found in the dorsal horn (Fig. 1) .
Densitometric analyses revealed a 33±7% and 51±10% increase in GABA B1 and GABA B2
protein levels, respectively, in the formalin-treated subjects as compared to controls.
Western blot analysis confirmed the change in GABA B2 subunit protein in response to formalin (Fig. 2) . In this case there was a 66% increase in the level of GABA B2 protein detected 24 hr following the subcutaneous injection of 5% formalin into the hind paw. As the GABA B1
antibody was inadequate for Western blot analysis it was not possible to utilize this analytical approach for this subunit.
Effect of Baclofen Administration on GABA B Receptor Subunit mRNA Levels.
Rats were injected (i.p.) with baclofen (5 mg/kg) twice daily for seven consecutive days and GABA B subunit mRNAs quantified in the lumbar dorsal horn of the spinal cord 24 hr after the last injection (Fig. 3) . While it has been established that this dosing schedule results in tolerance to the sedative and antinociceptive effects of baclofen (Enna et al., 1998) , no effect on 13 mRNA levels for either the GABA B1 or GABA B2 subunit, as compared to saline-treated control subjects, was noted under these conditions (Fig. 3 ).
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Chronic Administration of Baclofen and the Nociceptive Response to Formalin.
The effect of chronically administered baclofen on nociceptive threshold was examined in rats treated for seven consecutive days with 5 mg/kg baclofen (i.p., b.i.d.) by measuring their responses to painful stimuli 24 hr following the last injection of the GABA B agonist (Fig. 5) .
The results indicate that baclofen treatment causes a slight, but significant, increase in the number of late-phase formalin-induced hind limb flinches measured 30-40 min following injection of the chemogenic inflammatory stimulus. Likewise, there was a significant reduction in the latency to hind paw withdrawal in the mechanical pinch test following formalin administration to animals previously treated with baclofen, as compared to those receiving formalin alone (Fig. 5 ). In this case there was a nearly 50% reduction in latency observed with animals treated chronically with the GABA B receptor agonist.
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Discussion
The heterodimeric nature of the GABA B receptor distinguishes it from most other G protein-coupled sites. Indeed, GABA B receptor function appears to be absolutely dependent upon the expression of two separate gene products, their ability to dimerize and to remain united following insertion into the cell membrane (Kaupmann et al., 1998; Chronwall et al., 2001 ).
This multi-step process may render the GABA B receptors more vulnerable to disruption, and perhaps to pharmacological manipulation, than other G protein-coupled sites.
The present study was conducted to examine whether GABA B1 and GABA B2 subunits are employed solely for the formation of GABA B receptors by assessing the relationship between subunit expression and GABA B receptor function. The dorsal horn of the rat lumbar spinal cord was selected for study since it is anatomically well-defined and activation of GABA B receptors in this region alters nociception, an easily measured behavioral endpoint. The experiments were designed to determine whether changes in the production of these subunits are accompanied by a change in GABA B receptor function, and vice versa, which should occur if the subunits are utilized only for this purpose and only these two particular subunits dimerize to form a functional GABA B site. The results indicate a lack of concordance between subunit production and GABA B receptor function, suggesting that GABA B1 and GABA B2 may serve other functions besides forming GABA B receptors and indicating nongenomic mechanisms play an important role in the long-term down regulation of GABA B sites.
Earlier work revealed that formalin-induced hind paw inflammation increases both GABA B1 and GABA B2 subunit mRNA levels in the rat spinal cord (McCarson and Enna, 1999) .
This observation was extended in the present study with the discovery that formalin treatment increases GABA B1 and GABA B2 protein levels as measured by immunohistochemisry and, for GABA B2 at least, by Western blot analysis. Thus, the pain-induced increase in GABA B receptor subunit gene expression evoked by persistent inflammatory nociception is accompanied by an increase in protein synthesis. It was suggested previously this change in subunit expression may be due to a prolonged and massive release of GABA at these synapses in response to the peripheral pain stimulus (McCarson and Enna, 1999) . However, GABA B receptor occupancy, per se, apparently cannot fully explain the enhanced expression of the subunits since the results of the present study reveal that chronic (7 days) administration of baclofen, a selective GABA B receptor agonist, has no effect on either GABA B1 or GABA B2 subunit expression in the spinal cord.
Previous work indicated that chronic administration of baclofen decreases GABA B receptor number and causes tolerance to the pharmacological effects of this agent (Malcangio et al., 1995; Enna et al., 1998) . In the present study experiments were performed to define more precisely changes in GABA B receptor activity under this condition using in vitro and in vivo A lack of correlation between subunit gene expression and GABA B receptor function was also noted when the system was activated physiologically. Thus, there was a significant increase in GABA B receptor subunit mRNA levels (McCarson and Enna, 1999) and protein in the This article has not been copyedited and formatted. The final version may differ from this version. (White et al., 2000) . It is also conceivable that changes in the post-translational or post-transcriptional processing of the GABA B receptor subunits may change their pharmacological selectivity, rendering new sites insensitive to baclofen, and therefore undetectable by the assays performed in this study. Studies with GABA B1 knock-out mice suggest, however, this subunit is absolutely required for GABA B receptor activity (Schuler et al., 2001) , suggesting that any changes in the molecular structure of the receptor would be due primarily to a change in the GABA B2 component.
As for GABA B receptors in baclofen-tolerant animals, the present findings reveal that receptor number and function can be reduced significantly in the absence of any change in GABA B receptor subunit expression. While a number of nongenomic mechanisms, such as internalization and degradation, are important for short-term (minutes to hours) desensitization of G protein-coupled receptors in vitro (Perkins et al., 1991) , it appears longer-term (hours to days) modifications are due, at least in part, to genomic changes in receptor expression (Nishikawa et al., 1993; Karoor et al., 1996) . This does not appear to be the case for GABA B receptors. Thus, the lack of a change in GABA B receptor subunit expression following chronic (seven days)
This article has not been copyedited and formatted. The final version may differ from this version. with dephosphorylation leading to desensitization (Couve et al., 2002) . It is also possible that the reported change in the number of GABA B binding sites (Malcangio et al., 1995) , and the decline in receptor function noted in the present study, could be due to a post-transcriptional regulation of GABA B1 or GABA B2 subunit proteins. The lack of a decline in subunit gene expression, at a time when receptor activity is diminished, supports further the notion that these proteins serve functions other than formation of GABA B receptors. A better understanding of the mechanisms responsible for inducing and maintaining GABA B receptor desensitization should be of value in developing strategies for developing GABA B agonists that may be less likely to desensitize the receptor system (Enna et al, 1998) .
In summary, the results of the present study reveal that changes in GABA B receptor subunit expression is not necessarily accompanied by a change in receptor function, nor is a change in function indicative of a modification in the expression of these receptor subunits.
Thus, the results indicate that agonist-induced desensitization, even when prolonged, does not appear to be accompanied by genomic changes in receptor availability. Rather, the decline in receptor function appears likely due to an enhanced sequestration, degradation, or dephosphyorlyation of the receptor dimer. 
